Clinical Trial Update: Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating buspirone (Buspar) for depressive symptom improvement and neuroprotection in anxiety disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorder

Drugs mentioned

• BuSpar (buspirone hydrochloride)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Anxiety Disorder | Phase 4 | Status: WITHDRAWN